Experimental cell therapy takes aim at Hard-to-Treat cancers
NCT ID NCT06001684
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion twice per treatment cycle. The study will also look for early signs that the therapy might shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBR854 cell injection
What this could lead to
If successful, this could point toward a new cell-based treatment option for people with advanced solid tumors that have limited alternatives.
What could go wrong
This is an early phase 1 trial with only 19 participants, so safety and effectiveness are not yet established. Cell therapies can cause serious side effects, and the treatment may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized Cancer Vaccine ABO2109 Trial NCT07680582
- SCB0020160 First-in-Human Safety Trial (NCT07682337)
- SI-B036 Bispecific Antibody Trial for Solid Tumo NCT07678970
- YZJ-5053 for Advanced Solid Tumors – Phase 1 Tri NCT06209385
- REDIRICT: High-Dose Re-Irradiation Study (NCT05301101)
- SHR-4685 for Solid Tumors Phase 1 Trial NCT07676903
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China